Springer Nature [academic journals on nature.com], British Journal of Cancer, 1(119), p. 27-35, 2018
DOI: 10.1038/s41416-018-0132-8
Full text: Download
Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes.